In the past decade, with the advent of patient monitoring (e.g. coloscopy) or targeted therapy, great advancements towards the treatment of cancer in distinct patient cohorts were achieved. However, not all patients benefit from these new treatments . Furthermore, therapy failure in late-stage tumours by establishment of treatment escape mechanisms is a common observation in cancer, significantly affecting patient survival.
To broaden our understanding of disease causing mechanisms and to identify new target molecules for the treatment of cancer, we established an international, multi-disciplinary collaborative network with world-renowned experts in their respective fields. These comprise biochemists focusing on protein-protein interaction networks and mass spectrometric analysis, structural biologists assisting drug development, pharmaceutical chemists for drug synthesis, physicians and surgeons assisting in clinical translation.